Eddie Hickman

Jason Butler

Sumant Kulkarni

Kristen Kluska

Oren Livnat

Samantha Corwin

Brandon Folkes

Lachlan Hanbury-Brown

Louise Chen

Sami Corwin

- Zevra Therapeutics, a commercial stage rare disease company, has achieved a successful launch of Myalepta for Niemann Pick disease type C, converting approximately **40% of diagnosed patients** (129 out of 300-350) to prescription enrollment forms in the US within its first two full quarters.  **[1434647_tx_379743_0]** **[1434647_tx_379743_3]** 
- Myalepta has demonstrated **disease modification** with five years of OLE data showing halting of disease progression, and the company has filed for a **patent term extension** which is currently under review.  **[1434647_tx_379743_1]** **[1434647_tx_379743_2]** 
- Zevra is expanding Myalepta's market, having filed its Marketing Authorization Application (MAA) in Europe in July 2025, where it is now under review, and has increased European EAP enrollment to **89 patients** by Q2 2025.  **[1434647_tx_379743_5]** **[1434647_tx_379743_7]** 
- The company maintains a strong financial position with approximately **$217 million in cash**.  **[1434647_tx_379743_0]**

Zevra Therapeutics Provides Update on Myalepta Launch and Pipeline at Cantor Conference

ZEVRA THERAPEUTICS (ZVRA)